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SUMMARY
While formation of higher-order oncogenic transcriptional complexes is critical for RARa fusion
proteins in acute promyelocytic leukemia, the essential components and their roles in mediating
transformation are still largely unknown. To this end, the present study demonstrates that homo-
dimerization is not sufficient for RARa fusion-mediated transformation, which requires higher-order
homotetramerization. Surprisingly, intrinsic homo-oligomeric DNA binding by the fusion proteins is
also dispensable. Importantly, higher-order RXR/RARa fusion hetero-oligomeric complexes that
aberrantly recruit transcriptional corepressors to downstream targets are essential for transforma-
tion. Intervention of RXR-dependent pathways by panRXR-agonists or RXRa shRNAs suppresses
RARa fusion-mediated transformation. Taken together, these results define the oncogenic threshold
for self-association and reveal the pathological significance of higher-order RARa fusion/RXR
hetero-oligomeric complexes and their potential value as a therapeutic target.INTRODUCTION
Acute leukemia is characterized by the presence of recur-
rent chromosomal abnormalities, which frequently results
in formation of chimeric transcription factors (Look, 1997).
A common theme shared by most of these leukemia-
associated transcription factors (LATFs) is an acquisition
of additional self-association domains (homodimerization
and/or homo-oligomerization domains) from the fusion
partners (So and Cleary, 2004). Emerging evidence indi-
cates indispensable functions of these self-association
domains in various LATFs, including MLL (Martin et al.,
2003; So et al., 2003b), RARa (Kwok et al., 2006; Sterns-
dorf et al., 2006), and AML1 (Liu et al., 2006), fusions36 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.that account for the majority of the acute myeloid leukemia
(AML). In all cases, disruption of self-association abro-
gates transformation. Moreover, forced self-association
of truncated MLL (Martin et al., 2003; So et al., 2003b) or
RARa (Lin and Evans, 2000; Minucci et al., 2000) via
synthetic homodimerization/oligomerization domains
can closely recapitulate many biochemical and transcrip-
tional properties of bona fide fusion proteins and are capa-
ble of transforming primary hematopoietic cells (Kwok
et al., 2006; Martin et al., 2003; So et al., 2003b; Sternsdorf
et al., 2006). While these findings reveal a critical role of
aberrant self-association in acute leukemogenesis, the
underlying transformation mechanisms are still largely
unknown.SIGNIFICANCE
Emerging evidence indicates formation of higher-order transcriptional complexes as an essential step by various
leukemia-associated transcription factors (LATFs), including MLL, RARa, and AML1, that account for the majority
of acute myeloid leukemia (AML). To gain further insights into the underlying mechanisms, the present study func-
tionally separates homodimerization and intrinsic homo-oligomeric DNA-binding properties of RARa fusions from
transformation of primary hematopoietic cells. We reveal essential functions of homotetramerization and RXR
recruitment, which results in the formation of higher-order hetero-oligomeric DNA-binding complexes that are
required for RARa fusion-mediated transformation. These findings not only identify the key elements and potential
avenues for therapeutic targeting of RARa-mediated leukemia, but also shed light on oligomeric transformation
mechanisms reported with various LATFs.
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Functional Dissection of RARa Fusion ComplexesRetinoic acid receptor a (RARa) fusion associates with
almost 100% of acute promyelocytic leukemia (APL),
which is uniquely sensitive to differentiation therapy with
all-trans retinoic acid (ATRA) (Zelent et al., 2001). While
wild-type RAR binds DNA very weakly, heterodimerization
with retinoid X receptors (RXR) increases DNA-binding
strength and defines the heterodimer-selective RA
response element (RARE) repertoire (Chambon, 1996). In
the absence of agonists or in the presence of antago-
nists/inverse agonists, the heterodimer represses the
expression of certain target genes by recruiting corepres-
sor complexes, containing histone deacetylases (HDAC)
that silence gene expression by altering chromatin struc-
ture. ATRA binding results in allosteric conformational
changes of the RARa/RXRa heterodimer resulting in
dissociation of corepressor complexes and recruitment
of histone acetyltransferase (HAT) containing coactivator
complexes (Chen et al., 1997; Germain et al., 2002; Kuro-
kawa et al., 1995; Onate et al., 1995). Conversely, onco-
genic RARa fusions acquire high-affinity corepressor
interaction ability, leading to constitutive transcription re-
pression of their downstream target genes even in the
presence of physiological levels of ATRA (Grignani et al.,
1998; Guidez et al., 1998; He et al., 1998; Lin et al.,
1998). To date, in APL patients five different RARa fusions
have been identified, all of which result in direct fusion of
self-association domains from the partners to the trun-
cated RARa protein (So and Cleary, 2004; Zelent et al.,
2001). Biochemically, self-association of truncated RARa
has been shown to confer (1) high-affinity binding with
transcriptional corepressor complexes in an ATRA-
dependent manner; (2) altered DNA-binding abilities as
homo-oligomeric RARa fusions and/or higher-order
hetero-oligomeric RARa fusions/RXRa complexes; and
(3) potential dominant-negative effects on the pathways
mediated by RARa partners (Dong et al., 2003; Dong and
Tweardy, 2002; Dong et al., 1996; Lin and Evans, 2000;
Minucci et al., 2000; Perez et al., 1993; Redner et al.,
2000; So et al., 2000). Biologically, the self-association do-
mains are also essential for RARa fusion mediated trans-
formation of primary hematopoietic cells. Direct fusion of
RARa with synthetic FKBP self-association domains is
capable of transforming primary hematopoietic cells, and
inducing leukemia in mice with long latency and reduced
penetrance (Kwok et al., 2006; Sternsdorf et al., 2006).
Conditional reversion of self-association can suppress
transformation of primary hematopoietic cells by RARa
fusion proteins (Kwok et al., 2006). While these findings
reveal a crucial role of self-association and highlight it as
a potential target for molecular therapy, we still have only
very limited knowledge of the underlying transformation
mechanisms, which are essential for rational drug target-
ing. For instance, it is not clear if there is an oncogenic
threshold for self-association (e.g., homodimerization ver-
sus homotetramerization), what are the compositions of
the oncogenic oligomeric effector complexes, and how
do they affect gene expression and transformation?
To gain further mechanistic insights into these issues,
the present study characterized the transformation mech-anisms mediated by oligomeric Stat5b-RARa, which has
two distinctive self-association domains, and exploited
structural data that provide an opportunity to molecularly
dissect the oncogenic threshold and functional require-
ments of self-association. We also investigated the impor-
tance of RXR in RARa fusion-mediated transformation.
RESULTS
Stat5b-RARa-Mediated Transformation of Primary
Hematopoietic Cells Is Dependent on the Highly
Conserved N-Terminal Domain but Not
the Coiled-Coil Domain
While Stat5b-RARa (SR) was initially identified in an APL
patient (Arnould et al., 1999), no transformation model is
available for this fusion. To this end, the oncogenic prop-
erty of SR in transformation of primary hematopoietic cells
was assessed by a retroviral transduction/transformation
assay (RTTA) that has successfully modeled the transfor-
mation properties of various LATFs including RARa fusion
proteins (Du et al., 1999; Kwok et al., 2006; So et al.,
2003a). As expected, primary bone marrow cells trans-
duced with empty-vector viruses exhausted their prolifer-
ative capability in the second round of plating (Figure 1A).
In contrast, SR-transduced cells acquired self-renewal
property and could form compact GM-CFU-like colonies
even in the third plating (Figures 1A and 1B). Immunophe-
notypic and histological analyses of the transduced cells
were consistent with the phenotype of myeloid precursors
(Figures 1B and 1C) reminiscent of PML-RARa- or PLZF-
RARa-transformed cells (Kwok et al., 2006). Since Stat5b
is activated in many forms of myeloid leukemia and consti-
tutively active Stat5b alone could transform primary he-
matopoietic cells and induce leukemia in mice (Moriggl
et al., 2005), we further showed that both the truncated
Stat5b and RARa alone did not exhibit any detectable
transformation property and failed to give colonies after
second plating (Figure 1A). Thus, the enhanced self-
renewal of primary hematopoietic cells mediated by SR
is dependent on contributions from both the Stat5b and
the RARa portions.
To gain further insights into the transformation mecha-
nisms and identify critical domains required for SR-medi-
ated transformation, we tested the myeloid transformation
ability of various deletion mutants targeting specific do-
mains in Stat5b (Dong and Tweardy, 2002). SR mutants
with deletion of the Stat5b DNA-binding domain (DDBD)
or SH2 domain (DSH) could still transform primary hema-
topoietic cells and gave compact third-round colonies,
indicating that neither of these two domains is required
for transformation (Figure 1A). Next, we tested the trans-
formation ability of SR mutants targeting individual self-
association domains. Unexpectedly, SR-DCC with dele-
tion of the coiled-coil homodimerization domain could still
efficiently transform myeloid progenitors and gave rise to
significant numbers of compact third-round colonies (Fig-
ures 1A and 1B). In contrast, SR-DN with deletion of the N-
terminal homotetramerization domain completely lost its
transformation property and failed to produce third-roundCancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 37
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Functional Dissection of RARa Fusion ComplexesFigure 1. Enhanced Self-Renewal of Primary Hematopoietic Cells by SR Requires N-Terminal Tetramerization Domain but Not the
Coiled-Coil Domain
(A) Schematic diagram of SR and mutants used in RTTA (left). The bar chart (right) represents the corresponding numbers of colonies after each plat-
ing in methylcellulose. Error bars indicate standard deviations (SD) of three independent experiments.
(B) Typical third-round colony (left) and cell morphology (right) of primary bone marrow cells transduced with indicated constructs. Scale bars in left
and right panel are 100 mm and 10 mm, respectively.
(C) Phenotypical analysis of cells transformed by SR. Blue profiles represent stainings obtained with antibodies specific for the indicated surface
markers. Red profiles show unstained controls.
(D) Western blot analysis with anti-RARa or anti-Flag antibodies shows expression of expected size proteins from all constructs used in RTTA.colonies (Figures 1A and 1B), although comparable level
of each mutant protein with expected size was detected by
western blotting (Figure 1D). Taken together, these results
suggest a specific requirement of homotetramerization for
RARa fusion-mediated transformation.
Higher-Order Homotetramerization Rather
Than Simple Dimerization Is Required for RARa
Fusion-Mediated Transformation
To characterize the self-association property of these
Stat5b domains in the context of RARa fusions, both
coimmunoprecipitation and gel filtration assays were per-
formed. Using an immunoprecipitation-western blot assay38 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.on 293 cells cotransfected with constructs expressing
Flag- or Myc-tagged SR, self-association was observed
in all the tested constructs but not in controls where the
Flag-tagged constructs were replaced by empty vector
(Figure 2A). These results confirm the presence of two dis-
tinctive self-association domains (N-terminal domain and
coiled-coil domain) in the SR fusion. To further distinguish
simple homodimerization from higher-order homo-oligo-
merization, gel filtration analysis was employed. In con-
trast to our previous results on PLZF-RARa, which almost
exclusively eluted at a sharp peak corresponding to the
estimated size of a homotetramer (Kwok et al., 2006),
full-length SR was eluted in multiple fractions with a major
Cancer Cell
Functional Dissection of RARa Fusion ComplexesFigure 2. Homodimerization Is Not Sufficient for RARa Fusion-Mediated Transformation, which Requires Higher-Order Homo-
tetramerization
(A) Cell lysates from cotransfected 293 cells were immunoprecipitated with anti-Flag antibody and western blotted with anti-Myc antibody.
(B and C) Gel filtration analysis using size exclusion column. Top panel shows the western blot using anti-RARa antibody on protein fractions collected
from indicated elution volumes (ml). Constructs used in the experiments are shown in the left. Bottom panels are the gel filtration chromatograms
plotting elution volume (ml) against intensity of the detected protein (%) with arrows indicating the elution volumes of corresponding size standard.
(D) Schematic diagram of SR point mutants and FKBP-RARa constructs (left) used in RTTA. The bar chart (right) represents the respective numbers of
colonies after each plating. Error bars indicate SD of two independent experiments.
(E) Typical third-round colony morphology of cells transduced with indicated constructs. Scale bars, 100 mm.Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 39
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Functional Dissection of RARa Fusion Complexespeak of estimated molecular size about 500 kDa, consis-
tent with a homotetramer. We also observed two minor
peaks with molecular size about 200 kDa and >1 MDa,
which could correspond to the sizes of a homodimer and
a higher-order homo-oligomer, respectively (Figure 2B).
Consistent with previous studies (Kwok et al., 2006;
Minucci et al., 2000), endogenous RXR were dissociated
from the RAR fusion complexes under stringent gel filtra-
tion conditions (Figure S1 in the Supplemental Data avail-
able with this article online). Analogous to the full-length
SR, SR-DDBD and SR-DSH mutants eluted in multiple
fractions covering homodimers, -tetramers, and –oligo-
mers, although their relative distributions may not be the
same (Figure 2B). Conversely, the SR mutants with dele-
tion of a single self-association domain (DCC or DN) ex-
hibited distinctive gel filtration elution profiles. The minor
peak >1 MDa disappeared in both cases, suggesting
that both self-association domains are required for the for-
mation of higher-order homo-oligomeric complexes. The
SR-DCC mutant was predominately eluted at a peak of
about 400 kDa corresponding to a homotetrameric com-
plex (Figure 2B). The SR-DN mutant was almost exclu-
sively eluted at a single fraction of about 200 kDa corre-
sponding to a homodimer (Figure 2B). These results
reveal that the N-terminal domain is responsible for forma-
tion of homotetramers, while the coiled-coil domain mainly
mediates homodimerization. Together with the transfor-
mation data, these results strongly suggest that homote-
tramerization rather than homodimerization is required
for RARa-mediated transformation.
Since the self-association domains in Stat5b can have
additional properties that may influence the transforma-
tion outcomes, we decided to validate this finding using
a FKBP synthetic self-association domain that has been
previously used for studying self-association property of
various LATFs including RARa (Kwok et al., 2006; Martin
et al., 2003; So et al., 2003b; Sternsdorf et al., 2006). To
this end, we constructed a synthetic 1xFKBP-RARa carry-
ing only one instead of four copies of the FKBP self-asso-
ciation domain and compared its self-association prop-
erty with the previously described 4xFKBP-RARa (Kwok
et al., 2006). In contrast to 4xFKBP-RARa, which dis-
played an elution profile with two major peaks corre-
sponding to homo-oligomeric and -dimeric complexes,
1xFKBP-RARa was almost exclusively eluted at a fraction
corresponding to a homodimer (Figure 2C), findings rem-
iniscent of the full-length and DN mutant of SR, respec-
tively. When these FKBP constructs were subjected to
transformation assays, 4xFKBP-RARa, as expected,
could efficiently enhance self-renewal of primary hemato-
poietic cells (Figure 2D&E). In contrast, cells transduced
with 1xFKBP-RARa had gradually lost self-renewal ca-
pacity and displayed severely compromised ability to
give rise to third-round colonies (Figure 2D). Western blot-
ting confirmed similar expression levels of these con-
structs with the expected sizes (Figure 1D). Thus, these re-
sults together with the SR data strongly suggest that
homodimerization is not sufficient for RARa fusion-medi-
ated transformation of primary hematopoietic cells, which40 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.requires instead homotetramerization or higher-order
homo-oligomerization.
Oncogenic SR Mutants and 4xFKBP-RARa Failed
toMediate Proficient Homo-Oligomeric DNABinding
Aberrant transcriptional repression of RA-responsive
genes is believed to be a major underlying transformation
mechanism of RARa fusion and is relieved by retinoic acid
therapy (Zelent et al., 2001). In contrast to the wild-type
RARa, which binds DNA only in the presence of RXRa,
we and others have shown that RARa fusion proteins via
the self-association domains in the fusion partners could
bind DNA either as homo-oligomers or hetero-oligomers
with RXRa (Dong et al., 2003; Dong and Tweardy, 2002;
Dong et al., 1996; Lin and Evans, 2000; Minucci et al.,
2000; Perez et al., 1993; Redner et al., 2000; So et al.,
2000). However, it is not clear if one or both of these
DNA-binding properties are required for transformation,
which may have critical implications for molecularly tar-
geted therapies. To this end, we performed extensive gel
shift analyses to assess the DNA-binding properties of
various SR proteins. As expected, full-length SR could
efficiently bind all tested RAREs as homo-oligomers
(Figure 3A). Analogous to the full-length fusion, both
SR-DDBD and the SR-DSH could also bind and exhibited
similar RARE-binding patterns (Figure 3A). Conversely,
SR-DN exhibited reduced DNA-binding abilities as com-
pared with the full-length construct (Figure 3A). Sur-
prisingly, the DNA-binding property of SR-DCC was sig-
nificantly compromised even though it could efficiently
transform primary hematopoietic cells. Proteins levels
used in the assays were normalized by coupled in vitro
transcription and translation assay using 35S methionine
(Figure 3B). The poor DNA-binding ability of transforma-
tion-competent SR-DCC suggests that homo-oligomeric
DNA binding may not be essential for transformation.
Based on available crystal structural data and homology
alignment among the Stat family proteins (Chen et al.,
1998, 2003), we further developed and characterized sev-
eral SR point mutants, three of which had maintained most
properties of the full-length SR with the exception of their
intrinsic homo-oligomeric DNA binding. Analogous to the
SR-DCC mutant, all these mutants (SR-FL W37A; SR-FL
F81A; SR-FL L82A) with a single point mutation at the
N-terminal domain failed to bind DNA as homo-oligomeric
complexes (Figure 3A). However, all of them maintained
their ability to form homo-oligomeric, -tetrameric, and
-dimeric complexes (Figure 2C). When these homo-
oligomeric DNA-binding-deficient SR point mutants were
assessed for their abilities to transform primary bone mar-
row cells, all maintained their transformation ability and
gave rise to significant numbers of third-round compact
colonies (Figures 2D and 2E). Consistently, both immuno-
phenotype and morphology of the transformed cells were
indistinguishable from those of full-length SR-transformed
cells (Figure 2E and data not shown). The appropriate ex-
pression of each construct was confirmed by western
blotting (Figure 1D). While these results strongly suggest
that homo-oligomeric DNA binding is dispensable for
Cancer Cell
Functional Dissection of RARa Fusion ComplexesFigure 3. Intrinsic RARa Fusion Protein Homo-Oligomeric DNA Binding Is Not Required for Transformation
(A) Gel shift assays were performed with in vitro translated proteins (indicated in the left) using different RAREs (shown on top).
(B) Appropriate protein expression from constructs used for gel shift assays was confirmed by in vitro transcription/translation using 35S-Met.
(C) Gel shift assays with ‘‘relaxed’’ forms of RAREs (left) using constructs indicated on top.SR-mediated transformation, it is not clear if this is spe-
cific to SR or common for other RARa fusion proteins.
We therefore assessed the DNA-binding properties of
the synthetic 4xFKBP-RARa fusion, which can closely
mimic the biochemical, transcriptional, and transforma-
tion properties of bona fide RARa fusions (Kwok et al.,
2006). Analogous to the SR-DCC and the point mutants,
4xFKBP-RARa homo-oligomers failed to bind to any of
the RAREs (Figure 3A).
Since homo-oligomeric RARa fusions have been spec-
ulated to bind to more relaxed RAREs such as DR8G,
DR12G, and ER8G (Kamashev et al., 2004), we tested
the ability of various RARa fusions to bind these RAREs.
While full-length SR and SR-DN bound efficiently to these
RAREs, all the SR point mutants and 4xFKBP-RARa failed
to bind to DNA, although very weak binding was observed
in SR-DCC (Figure 3C). In contrast to Kamashev et al., the
wild-type RARa/RXRa heterodimer exhibited strong bind-
ing to all these relaxed forms of RAREs (Figure 3C), which
was, however, not entirely unexpected in view of earlier
reports (Kato et al., 1995; Tavera-Mendoza et al., 2006).
The specificity of these bindings was confirmed by super-
shift assays using antibodies against RARa or RXRa
(Figure S2). Taken together, the absence of DNA-bindingability in various transformation-competent RARa mu-
tants indicates that homo-oligomeric DNA binding is not
critically required for oncogenic transformation mediated
by RARa fusions.
Higher-Order Hetero-Oligomeric SR/RXRa
and 4xFKBP-RARa/RXRa Complexes Are the
Dominant DNA-Binding Forms
Although our results uncoupled homo-oligomeric DNA
binding from transformation, RARa fusions could poten-
tially bind DNA as hetero-oligomers with RXR. To this
end, we assessed their DNA-binding properties when
complexed with RXRa. While the full-length SR efficiently
bound RAREs as homo-oligomers, the presence of RXRa
completely converted the SR homo-oligomers into SR/
RXRa hetero-oligomers (Dong and Tweardy, 2002), which
display a significantly relaxed DNA-binding selectivity
compared to homo-oligomers (for example, bindings to
DR1G, HoxB1, or p21 in Figure 4A). To further validate
these results in vivo, we analyzed the DNA-binding com-
plex in primary cells transformed by SR or MLL-ENL. Con-
sistent with the in vitro data, SR binds DNA in vivo as
hetero-oligomeric complexes with endogenous RXR
(Figure 4B). More strikingly, RXRa could complex withCancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 41
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Functional Dissection of RARa Fusion ComplexesFigure 4. SR Forms Hetero-Oligomeric
Complexes with RXRa and Corepressor
SMRT to Bind RAREs
(A) Direct comparison between SR homo-olig-
omeric DNA binding and hetero-oligomeric
DNA binding with RXR. Complex 1 and 2 refer
to two different RARa fusion complexes with
different apparent molecular sizes.
(B) Nuclear extracts from SR- or MLL-ENL-
transformed primary cells were subjected to
gel shift assay using DR5G. Retardation was
compared to in vitro transcribed/translated
(IVT) homo- and hetero-oligomeric complexes.
(C) Gel shift assays were performed with
in vitro translated proteins (indicated in the
left) together with RXRa using different RAREs
(shown above). Arrows indicate RARa fusion/
RXRa hetero-oligomeric complex. Asterisk
shows homodimeric RXRa complex.
(D) IVT proteins (shown above) together with
RXRa were used for gel shift assays using
DR5G oligo with increasing amounts of SMRT
in the absence or presence of indicated
amounts of ATRA.DNA-binding-deficient SR mutants to confer RARE bind-
ing (Figure 4C). These results strongly suggest that the
higher-order SR/RXRa hetero-oligomer rather than the
SR homo-oligomer is the dominant DNA-binding module.
Consistently, similar data obtained with 4xFKBP-RARa
further supported that higher-order RXRa hetero-oligo-
meric complexes correspond to the actual DNA-binding
species derived from RARa fusion proteins (Figure 4C).
To further characterize the transcriptional properties of
these higher-order hetero-oligomeric DNA-binding com-
plexes, we assessed their ability to associate with the
transcriptional corepressor SMRT and responses to
ATRA treatment. RARa/RXRa heterodimers could bind
to SMRT, but quickly dissociate at low concentration of
ATRA (i.e., 108 M) (Figure 4D). In contrast, the binding
of SMRT to SR/RXRa hetero-oligomers was refractory to
ATRA treatment even at the concentration of 106 M
(Figure 4D). Similarly, the association between 4xFKBP-
RARa/RXRa hetero-oligomers and SMRT was more resis-
tant to ATRA treatment (Figure 4D). Taken together, these
results indicate that higher-order RARa fusion/RXRa het-
ero-oligomeric complexes can efficiently bind RAREs
and associate with transcriptional corepressors that are
refractory to physiological concentration of ATRA.42 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.RXRa Is Required for Both Bona Fide and Synthetic
RARa Fusion-Mediated Transformation
To further interrogate the roles of RXRa in APL, we em-
ployed a shRNA approach to evaluate its functional re-
quirement for RARa fusion-mediated transformation of
primary hematopoietic cells. Two independent shRNAs
(sh563 and sh131) targeting murine RXRawere developed
and validated for their ability to efficiently knock down the
expression of murine RXRa (Figure 5A). Retroviral con-
structs carrying RARa oncoproteins were cotransduced
with either RXRa shRNA or vector control. Although re-
duced numbers of colonies were obtained in the first plat-
ing due to lower transduction efficiency for simultaneous
integration of two viruses into the genome, cells cotrans-
duced with SR and vector control rapidly expanded and
efficiently formed third-round compact colonies indistin-
guishable from the cells transduced with SR (Figures 5B
and 5C and Figures S3A and S3B). Conversely, cells co-
transduced with SR and either RXRa shRNA gradually
lost self-renewal property and displayed significantly
compromised ability to form third-round colonies in spite
of a transient expansion in the second plating. These
RXRa shRNAs also inhibited the ability of 4xFKBP-RARa
to confer self-renewal, suggesting general and a critical
Cancer Cell
Functional Dissection of RARa Fusion Complexesfunction of RXRa in RARa fusion-mediated transformation
(Figures 5B and 5C and Figures S3A and S3B). To control
for general toxicity and specificity of the shRNAs, they
were independently cotransduced with retroviruses
carrying a non-RARa oncoprotein, MLL-ENL. In contrast
to RARa oncoproteins, neither of these RXRa shRNAs
had any significant effect on MLL-ENL-mediated transfor-
mation (Figures 5B and 5C and Figures S3A and S3B).
To further extend the role of RXRa to the most common
RARa fusion found in the human disease, we validated
two independent shRNAs (sh616 and sh617) against
human RXRa and tested their efficacy in inhibiting the
growth of a PML-RARa leukemic cell line, NB4 (Figure 5D).
Knockdown of hRXRa expression using sh616 or sh617
consistently resulted in (1) significant inhibition of prolifer-
ation (Figure 5E), (2) nearly complete ablation of clono-
genic colony formation (Figure 5F and Figure S4), (3)
loss of mitochondrial membrane potential (Figure 5G),
and (4) induction of apoptosis (Figure 5G). In contrast, rel-
atively mild impacts on differentiation were observed, as
revealed by CD11c differentiation marker analysis (Fig-
ure S5). None of these effects were seen in cells trans-
duced with the control shRNA construct, which did not
affect the expression of endogenous hRXRa (Figures
5D–5G).
Clinically, it is known that a significant portion of APL
patients develop ATRA resistance as a result of clonal
evolution that selects for clones with mutations affecting
the ATRA response such as ligand-binding domain in
RARa (Lengfelder et al., 2005). Since our current approach
directly targets RXR instead of RAR, we sought out to
determine if it would also be effective for this subgroup,
which is refractory to ATRA treatment and has a poor
prognosis. We tested the efficacy of these two shRNAs
in inhibiting the NB4-MR2 cells, an ATRA-resistant sub-
clone derived from NB4 cells (Shao et al., 1997). In spite
of their inert responsiveness to ATRA, each of these RXRa
shRNAs could effectively (1) inhibit proliferation (Fig-
ure 5E), (2) ablate clonogenic colony formation (Figure 5F
and Figure S4), (3) induce loss of the mitochondrial mem-
brane potential, and (4) apoptosis (Figure 5G) but had ap-
parently minimal, if any, effect on NB4-MR2 differentiation
(Figure S5). Taken together, these results suggest that
RXRa is a critical component for RARa fusion-mediated
transformation and presents as a promising target for
ATRA-resistant APL.
Inhibition of RARa Fusion-Mediated Transformation
by RXR Agonist
To investigate the potential therapeutic value of targeting
RXRa-mediated pathways in RARa fusion-mediated
transformation, we used a well-characterized panRXR ag-
onist, SR11237, which has been previously tested in com-
bination with 8-CPT-cAMP, a protein kinase A (PKA) ago-
nist, for the induction of differentiation and apoptosis of
AML cell lines and patients’ blasts (Altucci et al., 2005; Be-
noit et al., 1999). After the second plating, SR-transduced
cells were split and plated into the third round in the ab-
sence or presence of SR11237. To demonstrate that theprimary transformed cells from this assay are pathologi-
cally relevant to the human disease, the transduced cells
were treated with ATRA. In contrast to untreated controls,
where SR-transduced cells efficiently formed third-round
colonies, cells treated with a pharmacological concentra-
tion (1 mM) of ATRA lost their self-renewal property and
significantly compromised their ability to form third-round
colonies, confirming the physiological relevance of these
primary transformed cells (Figures 6A and 6B). When SR-
transduced cells were treated with a combination of 100
mM 8-CPT-cAMP and 1 mM SR11237, a very significant
growth inhibition (mean = 70%) was observed as com-
pared with the mock control (Figures 6A and 6B). More in-
terestingly, when cells were treated with 1 mM SR11237
alone, we also observed a significant inhibitory effect
(mean = 50%) on colony formation (Figure 6A). To deter-
mine if this suppression is specific to SR or a more general
phenomenon for RARa fusion-mediated transformation,
we tested other RARa oncoproteins, including PML-
RARa and 4xFKBP-RARa, and observed very similar in-
hibitory effects (Figure 6A). Notably, inhibition was not
due to general toxicity of the drugs, as MLL-ENL-trans-
formed cells were inert to these treatments (Figures 6A
and 6B).
To further explore the mechanisms underlying the ob-
served rexinoid effect, primary cells transformed by SR
or MLL-ENL (control) were treated with SR11237 in com-
bination with PKA or various retinoid antagonists. That
1 mM SR11237 still efficiently inhibits colony formation
by SR-transformed cells even when coexposed to
100 mM RP-cAMP (a potent PKA inhibitor) suggested
that this inhibitory effect was not related to cAMP-induced
RXR desubordination (Figure 6C). To investigate if the ob-
served rexinoid inhibition depended on transcriptionally
active RARa/RXRa, which is required for ATRA-induced
differentiation (Zelent et al., 2001), SR-transformed pri-
mary cells were treated with SR11237 and 1 mM of an
RARa-specific antagonist (BMS614) or an inverse pan-
RAR agonist (BMS493), which inhibits the transactivation
by stabilizing corepressors binding to RAR (Altucci et al.,
2005; Benoit et al., 1999; Germain et al., 2002). However,
neither the RAR antagonist nor the inverse agonist had
negative effect on SR11237-induced inhibition, strongly
indicating a mechanism different from ATRA-induced dif-
ferentiation (Figure 6C). Consistently, distinct results were
obtained when the primary transformed cells were ana-
lyzed for differentiation markers after rexinoid or retinoid
treatment. As expected, ATRA induced significant differ-
entiation in primary transformed cells as reflected by its
pronounced reduction in expression of c-kit progenitor
marker and increased expression of myeloid differentia-
tion markers Mac-1 and Gr-1 (Figure 6D). In stark contrast,
SR11237-treated cells displayed only very mild effects on
expression of these markers, whereas SR11237 together
with cAMP analog displayed intermediate effects (Fig-
ure 6D). All this reveals that the observed rexinoid inhibi-
tion is distinct from ATRA-induced differentiation and
cAMP/rexinoid-induced RXR desubordination. Consis-
tently, SR11237 induced only weakly (<5-fold) theCancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 43
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Functional Dissection of RARa Fusion ComplexesFigure 5. Expression of RXRa Is Required for RARa Fusion-Mediated Transformation
(A) Cell lysates from cotransfected 293 cells were western blotted with murine anti-RXRa (Santa Cruz) or anti-actin (Sigma) antibody as indicated. The
results of two independent experiments are shown.
(B and C) The bar chart represents the relative numbers of third-round colonies of primary hematopoietic precursors cotransduced with retrovirus
carrying fusion gene and empty vector or sh563 (B) or sh131 (C). Error bars indicate SD of two independent experiments.
(D) Lysates from transduced NB4 cells were blotted with anti-hRXRa antibody (provided by Hinrich Gronemeyer) and anti-actin antibody as indicated.44 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.
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Functional Dissection of RARa Fusion Complexesexpression of an RARa-inducible gene, RARb, which was,
however, strongly upregulated (>150-fold) by ATRA in pri-
mary transformed cells (Figure 6E). Since pure rexinoids
have been reported to induce apoptosis (Benoit et al.,
2001; Aure´lie Rossin, P.S., Annica Jacobson, Lucia
Altucci, and H.G., unpublished data), which is consistent
with our RXR shRNA data (Figure 5), and the observation
of its modest impact on differentiation, we speculated
that the effect of SR11237 might be a result of induction
of apoptosis. Indeed, we could detect a significant loss
of mitochondrial membrane potential and a dramatic
induction of apoptosis (from 32% to 72%) by SR11237
in primary transformed cells (Figure 6F). These results
support once more that SR11237-induced apoptosis
is different from ATRA-induced differentiation or cAMP/
rexinoid-induced RXR desubordination.
Previous studies have shown that rexinoids have the
potential to induce apoptosis in various cell lines under
low-serum conditions even in the absence of functional
RARa (Benoit et al., 2001; Aure´lie Rossin, P.S., Annica
Jacobson, Lucia Altucci, and H.G., unpublished data).
To further investigate the rexinoid-induced apoptosis in
full-blown PML-RARa leukemic cells, NB4 cells were
treated with SR11237 in the absence or presence of vari-
ous apoptotic inhibitors under low-serum conditions (Fig-
ure 7). Analogous to the primary cell data, we detected
significant induction of apoptosis (from 12% to 80%) (Fig-
ures 7A and 7B), activation of effector caspases (caspase
3/7) (Figure 7C), and loss of mitochondrial membrane
potential (Figure 7D) in the presence of 1 mM SR11237.
Addition of a pan-caspase inhibitor (Z-VAD-FMK) inhibited
rexinoid-induced apoptosis, which was, however, inert to
inhibitors of reactive oxygen species (ROS) such as L-NAC
and GSH antioxidants (Figures 7A and 7B and data
not shown). When cells treated with various rexinoids/
retinoids were analyzed for apoptosis and expression of
the CD11c myeloid differentiation marker, SR11237 alone
induced significant apoptosis but not expression of
CD11c, while ATRA or SR11237 in combination with
cAMP analogs dramatically increased the CD11c expres-
sion without significant induction of apoptosis under iden-
tical experimental conditions (Figure 7D). Consistently,
addition of Z-VAD-FMK caspase inhibitor suppressed
SR11237-induced apoptosis without altering the differen-
tiation status of the cells (Figure 7D). Taken together,
these results reveal a critical cAMP-independent function
of RXR agonists in inducing apoptosis without prior differ-
entiation in RARa fusion-transformed cells.
DISCUSSION
Self-association, a widely used process for regulation of
activity and specificity of proteins such as kinases andtranscription factors involved in various biological pro-
cesses, is frequently hijacked by oncoproteins to activate
their oncogenic potential (So and Cleary, 2004). While the
discovery of essential roles of self-association in mediat-
ing transformation of primary hematopoietic cells by vari-
ous LATFs (Kwok et al., 2006; Liu et al., 2006; Martin et al.,
2003; So et al., 2003b; Sternsdorf et al., 2006) has opened
up an avenue for molecular targeting, it is not clear
whether the targeting endpoint is homodimer or mono-
mer, or if it is technically feasible to efficiently disintegrate
oligomers into monomers. A recent study on AML1-ETO
has indicated that a complete dissociation of tetrameric
fusion into monomers can pose a serious technical chal-
lenge due to the relatively large hydrophobic interfaces
that are frequently found in oligomers (Liu et al., 2006).
Thus, defining the self-association threshold becomes
a critical issue for not only understanding the underlying
molecular mechanisms but also designing rational drug
targeting. Using Stat5b-RARa with two distinctive self-
association domains as a working model, we demonstrate
that loss of homotetramerization, albeit with retention of
homodimerization property, abolished its ability to trans-
form primary hematopoietic cells. Similarly, simple homo-
dimerization of truncated RARa by synthetic dimerizing
modules (e.g., 1xFKBP) is not sufficient to mediate trans-
formation, which requires higher-order homo-oligomeri-
zation (e.g., 4xFKBP). These results strongly suggest
that disruption of homotetramers into homodimers in-
stead of monomers may already be sufficient to abrogate
the transformation ability of RARa oncoproteins. In con-
trast to the oligomerization domain of ETO in the AML1-
ETO fusion protein, where the amphipathic monomer
interacts with three other monomers through hydrophobic
interactions that bury an extensive accessible surface
area (ASA) of about 10K A˚2 (Liu et al., 2006), the N-terminal
tetramerization domain of Stat proteins mediates the for-
mation of homotetramers between two dimers with a total
ASA of only about 2K A˚2 (Chen et al., 1998, 2003; Vinke-
meier et al., 1998). More important, introduction of single
point mutations in the N-terminal domain can abrogate
homotetramerization of Stat proteins, suggesting rela-
tively small or weak interaction interfaces, although any
equivalent mutations will have to be empirically deter-
mined and validated in the context of RARa fusions. By
defining the oncogenic threshold beyond homodimeriza-
tion, the present study underscores the therapeutic poten-
tial of targeting the oligomerization properties in at least
some RARa oncoproteins (Figure 8A).
While RAR alone is a poor DNA-binding protein unless
heterodimerized with RXR (Chambon, 2005), we and
others have previously shown that RARa fusion homo-
oligomers acquire additional DNA-binding properties in-
dependent of RXR (Dong et al., 1996, 2003; Dong and(E) Transduced NB4 (upper bar chart) and NB4-MR2 cells (lower bar chart) were subjected to MTS assay. Error bars indicate SD of two independent
experiments.
(F) Typical INT-stained colony pictures of transduced NB4 (upper panel) and NB4-MR2 cells (lower panel) 6 days after plating in methylcellulose.
(G) Transduced NB4 (left side) and NB4-MR2 cells (right side) were analyzed for apoptosis using Annexin V/PI (upper panel) and mitochondrial mem-
brane potential using DIOC6(3) (lower panel).Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 45
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Functional Dissection of RARa Fusion ComplexesFigure 6. RXR Agonist Inhibits RARa Fusion-Mediated Transformation of Primary Cells by Inducing Apoptosis without Prior
Differentiation
(A) The bar chart represents the relative numbers of third-round colonies of primary bone marrow cells transduced with indicated constructs (left).
Error bars indicate SD of five independent experiments.
(B) Typical third-round colony morphology in the absence or presence of indicated drugs generated from transduced bone marrow cells as indicated.
Scale bar, 100 mm.46 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.
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Functional Dissection of RARa Fusion ComplexesTweardy, 2002; Lin and Evans, 2000; Minucci et al., 2000;
Perez et al., 1993; Redner et al., 2000; So et al., 2000).
However, it is not clear which of these DNA-binding prop-
erties are critical for transformation or if both are required.
In this study, we uncouple homo-oligomeric DNA binding
from RARa fusion-mediated transformation by identifying
several transformation-competent but homo-oligomeric
DNA-binding-deficient mutants derived from both bona
fide and synthetic RARa fusions. We also reveal higher-
order hetero-oligomeric RXR/RARa oncoproteins as the
dominant DNA-binding species to which RXRa confers
specific DNA-binding properties to otherwise DNA-bind-
ing-deficient but transformation-competent RARa mu-
tants, thereby revealing an important role of RXRa in mod-
ulating the transcription and transformation properties of
oncogenic RARa fusion proteins (Figure 8B). While RXRa
is a limiting cofactor for various nuclear receptors (Cham-
bon, 2005), which may also be interfered and contribute to
the repression phenotype observed upon shRNA and/or
panRXR agonist treatment, these effects will be relatively
minor, as primary hematopoietic cells transformed by MLL
fusion were refractory to these treatments. Thus, interven-
tion of RXRa-mediated pathways may represent a promis-
ing therapeutic avenue for effective targeting oncogenic
RARa fusion complexes, particularly for ATRA-resistant
APL cells (Figures 8B–8D).
Whereas ligand-dependent transactivation function of
RXR is subordinated to some of its heterodimeric part-
ners, such as wild-type RARs (Germain et al., 2002; Gro-
nemeyer et al., 2004), crosstalk with other signaling path-
ways such as the one activated by elevated levels of
intracellular cAMP can cause RXR desubordination due
to corepressor release from the RAR partner (Altucci
et al., 2005). PanRXR agonists had previously been used
in conjunction with cAMP analogs or other RARa agonists
to induce differentiation of both APL cells (Benoit et al.,
1999; Kamashev et al., 2004) and RA-insensitive non-
APL AML leukemic blasts (Altucci et al., 2005), suggesting
that the molecularly targeted pathways by rexinoid can be
context dependent, particularly in full-blown leukemic
blasts or established cell lines. The present study reveals
that combinatorial treatment with a pure rexinoid in the
presence of elevated cAMP levels efficiently phenocopies
the effect of ATRA with respect to the inhibition of growth/
self-renewal of RARa fusion-transformed primary hema-
topoietic precursor cells (Figure 8C). Notably, we also ob-
serve a similar inhibition, albeit less pronounced, when
using the rexinoid alone and demonstrate that SR11237
alone can activate caspase-mediated apoptosis, which
is independent of cAMP and is different from ATRA-in-
duced differentiation (Figure 8D). In established cell lines
such as NB4, rexinoid-induced apoptosis is only observedin low-serum conditions when growth factors become lim-
ited. It is therefore an attractive hypothesis that the initial
transformation event of hematopoietic precursors by
RARa fusion oncoproteins may alter their growth factor
requirements, possibly revealed by their altered self-
renewal, but at the same time make them vulnerable against
rexinoid-induced apoptosis. However, as transformed
clones evolve, they acquire secondary mutations, such as
activated Flt3 (Sohal et al., 2003), that reduce the growth
factor dependence and may desensitize the response
to rexinoid-induced apoptosis. Therefore, combinations
of growth factor antagonists and rexinoids may represent
alternative ways to target RARa fusion-transformed cells
(Figure 8D).
Taken together, our results reveal formation of higher-
order homotetrameric complexes and recruitment of
RXRa as two essential components and potential thera-
peutic targets for RARa fusion-mediated transformation
(Figure 8), thus further endorsing the therapeutic potentials
of RXR agonists, which have already been used for treat-
ment of cutaneous T cell lymphoma (Zhang and Duvic,
2003) and non-small-cell lung cancer (Rigas and Dragnev,
2005). Although the combination of ATRA and chemother-
apy has greatly improved the overall survival of APL pa-
tients (Degos and Wang, 2001), there are still significant
numbers of relapsed cases, which become ATRA resis-
tant, and only half of them will respond to arsenical treat-
ment (Lengfelder et al., 2005). Thus, future effort in identi-
fying and validating additional molecular targets such as
RXRa will provide not only important insights into APL
pathogenesis but also effective therapeutic approaches,
particularly for ATRA-resistant or relapsed APL patients.
EXPERIMENTAL PROCEDURES
Constructs
All the Stat5b-RARa (Dong and Tweardy, 2002), PML-RARa, FKBP-
RARa (Kwok et al., 2006), GST-SMRT, and RXRa (Dong and Tweardy,
2002; So et al., 2000) constructs have been previously reported. The
single point mutants of SR were made using the primer extension ap-
proach and have been fully sequenced across the amplified fragments.
Details of shRNA constructs are described in the Supplemental Exper-
imental Procedures.
RTTA
RTTA was performed as previously described (Kwok et al., 2006). For
knockdown experiments, spinoculation was repeated three times
before the plating. In vitro transformation was defined as enhanced
self-renewal of primary hematopoietic cells beyond three rounds of
plating in the serial replating assay.
Lentiviral Transduction, Clonogenicity, and Proliferation Assay
Lentiviral supernatant collected 48 hr after transfection of 293 cells
was added to NB4 cells in the presence of 5 mg/ml polybrene for(C) The bar chart shows the relative numbers of third-round colonies of SR- and MLL-ENL-transduced primary cells. Error bars indicate SD of two
independent experiments.
(D) Primary cells transduced with SR were treated as indicated for 48 hr and analyzed for surface marker expression by FACS.
(E) RT-Q-PCR analysis for murine RARb (mRARb) on cDNA samples prepared from SR-transduced primary cells treated with indicated rexinoid/
retinoid. Error bars indicate SD of two independent experiments.
(F) FACS plots show Annexin V/PI (upper panel) and DiOC6(3) (lower panel) stainings of SR-transduced primary cells.Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 47
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Functional Dissection of RARa Fusion ComplexesFigure 7. RXR Agonist Induces Caspase-Mediated Apoptosis in NB4 Cells without Prior Differentiation
(A) The bar chart represents the percentage of apoptotic NB4 cells after treatment (as indicated) for 72 hr. Error bars indicate SD of two independent
experiments.
(B) FACS plots show Annexin V/PI staining of NB4 cells after treatment.
(C) The bar chart represents the fold induction of activated caspase 3 and 7 of treated NB4 cells relative to untreated control. The error bars indicate
SD of measurements carried out in duplicates.
(D) NB4 cells treated for 60 hr as indicated were analyzed by FACS for expression of CD11c surface marker (upper panel: dotted, unstained; red,
stained and untreated control; and blue, stained and treated samples), Annexin V/PI (middle panel), and DIOC6(3) (lower panel).48 Cancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc.
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Functional Dissection of RARa Fusion ComplexesFigure 8. Potential Therapeutic Avenues by Targeting Homo-Oligomerization or RXR-Mediated Pathways in APL
Suppression of transformation by disruption of homo-oligomerization (A); knockdown of RXRa by shRNAs that inhibits the formation of effective DNA-
binding complexes (B); pan-RXR agonist in combination of 8-CPT-cAMP by destabilizing the corepressor complexes and crosstalk with other cAMP-
activated pathways (C); RXR agonists alone via induction of apoptosis, which can potentially further be augmented by growth factor inhibitors (D).overnight transduction. Transduced cells were then selected for 3 days
in the presence of 1 mg/ml Puromycin. For clonogenicity assay, 2000
transduced NB4 cells were plated in 1% methylcellulose (Stem Cell
Technologies) and incubated for 6 days. Colonies were stained with
INT (p-Iodonitrotetrazolium Violet, Sigma) at 100 mg/ml final concentra-
tion. For proliferation assay, 10,000 transduced NB4 cells were plated
in triplicates into a 96-well microtiter plate in 100 ml volume. After 48 hr
or 72 hr, 20 ml of MTS reagent (CellTiter96 Aqueous One Solution,
Promega) was added and incubated for 1 hr in the dark at 37C. Absor-
bance was recorded at 490 nm using a Photospectrometer (Dynatech
Laboratories).
Phenotype Analysis
Immunophenotypic analysis was performed by FACS using fluoro-
chrome-conjugated monoclonal antibodies to human CD11c (BU15
clone) (Caltaq) and murine c-Kit (2B8 clone), murine Mac-1 (M1/70
clone), murine Gr-1 (RB6-8C5 clone), murine B220 (RA3-6B2 clone),
and murine CD3e (145-2C11 clone) (Pharmingen Inc. or eBiosciences
Inc.), respectively. Staining was generally performed on ice for 15 min
and washed twice before analysis using a BD LSR II system (Becton
Dickinson Inc.).
Gel Filtration Study
Gel filtration assays were performed as previously described (Kwok
et al., 2006). Collected fractions were analyzed by western blot using
anti-RARa C-20 polyclonal antibody (Santa Cruz Biotech).Coimmunoprecipitation Assay
The immunoprecipitation study was essentially performed as previ-
ously described (Kwok et al., 2006). The antibodies used in the immu-
noprecipitation assay were from Sigma-Aldrich (M2 anti-Flag anti-
body) and the Hybridoma Unit in the Institute of Cancer Research
(9E10 anti-Myc antibody).
Gel Shift DNA-Binding Assay
The gel shift assay was carried out as previously described (So et al.,
2000). The probes were made according to published sequences
(Kamashev et al., 2004; So et al., 2000). Supershift was performed
by incubating the indicated reaction in the presence of GST fusion pro-
teins or specific antibody (anti-RARa C-20 polyclonal antibody or anti-
RXRa D-20 polyclonal antibody from Santa Cruz Biotech).
Quantitative RT-PCR
RNA from primary cells was isolated using RNeasy mini (Qiagen) and
reverse transcribed using SuperscriptII (Invitrogen). Quantitative RT-
PCR (RT-Q-PCR) was carried out on a 7900HT Fast Real-Time PCR
system (Applied Biosystems) using the Taqman Fast Reagent technol-
ogy. Primer sequences are described in the Supplemental Experimen-
tal Procedures.
Assays for Apoptosis, Mitochondrial Membrane Potential,
and Caspase Activity
Apoptosis was examined by staining with Annexin V/PI according to
the manufacturer’s protocol (Biovision) and analyzed by flowCancer Cell 12, 36–51, July 2007 ª2007 Elsevier Inc. 49
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Functional Dissection of RARa Fusion Complexescytometry. Mitochondrial membrane potential was assessed by incu-
bating 23 105 cells with 50 nM DIOC6(3) (Invitrogen) for 30 min at 37C
and subsequently analyzed by flow cytometry. Selected viable NB4
and NB4-MR2 cells were prepared 48 hr prior to Annexin V/PI
and DiOC6(3) stainings. Caspase 3/7 activity was measured using
Caspase-Glo 3/7 Assay (Promega) according to the manufacturer’s in-
structions using MLX Microplate Luminometer (Dynex Technologies).
Supplemental Data
The Supplemental Data include Supplemental Experimental Pro-
cedures and five supplemental figures and can be found with this
article online at http://www.cancercell.org/cgi/content/full/12/1/36/
DC1/.
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